In a report released today, Serge Belanger from Needham maintained a Buy rating on Liquidia Technologies, with a price target of $54.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Serge Belanger’s rating is based on his constructive view of Liquidia’s strategic positioning and future growth prospects within the pulmonary hypertension market. He likely expects the company’s lead therapy and platform to gain greater commercial traction over time, supported by a favorable competitive landscape and meaningful unmet medical need.
Belanger also appears to view upcoming corporate and regulatory milestones as important value catalysts that can unlock further upside in the shares. In his assessment, the company’s risk‑reward profile, relative to its current valuation, justifies a Buy rating despite the typical development, reimbursement, and execution risks inherent in specialty pharma names like Liquidia.
Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Esperion, and Collegium Pharmaceutical. According to TipRanks, Belanger has an average return of 10.5% and a 47.08% success rate on recommended stocks.